LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new ...
Naxitamab plus GM-CSF demonstrated strong antitumor activity and manageable toxicity in high-risk neuroblastoma patients, ...
Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as Colony Stimulating Factor 2 (granulocyte-macrophage), is a cytokine originally identified for its role in promoting the ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Safety and efficacy of pucotenlimab combined with standard chemotherapy regimens in the neoadjuvant treatment of pediatric patients with intermediate or high-risk rhabdomyosarcoma: A phase I/II study.
New research is breaking ground in repurposing an FDA-approved drug as a potential treatment in Down syndrome and normal aging. The results suggest that GM-CSF may improve cognitive function in people ...
FRANKFURT, Germany — A novel agent has shown promise in the treatment of chronic myelomonocytic leukemia (CMML), a rare, aggressive malignancy of myeloid cells with an inherent risk of transforming ...
Savara Inc. recently reported that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled recombinant human GM-CSF for treating ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Sargramostim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback